Hackensack University Medical Center John Theurer Cancer Center Phase I Clinical Trials Program Boasts New Jersey’s Largest Number of Early-Phase Clinical Trials

Full spectrum of first-in-human protocols offer patients innovative therapies at the earliest stage of development

Boasting the largest number of early-phase clinical trials in New Jersey, John Theurer Cancer Center at Hackensack University Medical Center offers patients innovative therapies at the earliest stage of their development through its Phase I Clinical Trials Program.

The program continues to grow and now covers the entire spectrum of first-in-human protocols, with more than 30 phase I clinical trials — expanding from studies of targeted therapies to innovative immunotherapies and cellular technologies with the potential to revolutionize cancer care. Examples include:

• A phase 1 study of intraperitoneal MCY-M11 therapy for patients with advanced platinum-resistant ovarian, primary peritoneum, or fallopian tube cancer and patients with recurrent peritoneal mesothelioma after chemotherapy.
• A phase 1, open-label, multicenter study of FT516 in combination with monoclonal antibodies in patients with advanced solid tumors.
• A phase 1 Multi-Tumor, Bioavailability Study of Relatimab in Combination with This study will characterize the movement of drugs within the body, evaluate safety and determine to which extent the body can process relatlimab in combination with nivolumab in subjects with certain advanced solid tumors. John Theurer Cancer Center is the only participating site in the U.S. for this study and enrolled the entire study in just over 12 months, even during COVID-19.
• Four clinical trials actively studying the newest generations of CTLA4.
• A study of biomarker-directed, pembrolizumab (MK-3475) based combination therapy for advanced non-small cell lung cancer to investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer without prior systemic therapy.
• A dose escalation study to determine the safety and pharmacokinetics of MK-0482 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.
• A study to determine the safety and tolerability, and establish a preliminary recommended Phase 2 dose, of MK-4830 administered as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.
• A study to evaluate the safety, tolerability, and efficacy in participants with advanced/metastatic or recurrent malignancies who receive V937 in combination with pembrolizuma.